Company / Cash & Equivalents
Phibro Animal Health Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$68.0M
FY2025
5-year range
$41.3M / $74.2M
FY2021-FY2025
Trend
-3.6%
vs FY2024
Sector context
#167 of 207
Health Care
What the data says
Phibro Animal Health's cash & equivalents of $68M is lower than 81% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $34M in FY2018 to $74M in FY2022.
Based on SEC 10-K filings.
$68M in FY2025 with a 5-year CAGR of +13.4%.
Improved from $41M to $68M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- +13.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 207This company $68.0M Sector average $669.5M
▼
-89.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 3.6% year-over-year.
- Ranks #167 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.0M | -3.6% |
| FY2024 | $70.6M | +71.1% |
| FY2023 | $41.3M | -44.4% |
| FY2022 | $74.2M | +47.9% |
| FY2021 | $50.2M | +38.2% |
| FY2020 | $36.3M | -36.9% |
| FY2019 | $57.6M | +71.3% |
| FY2018 | $33.6M | -40.1% |
| FY2017 | $56.1M | +66.9% |
| FY2016 | $33.6M | +22.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026